3/31/2020  12:00:00 AM Chg. +2.80 Volume Bid5:29:55 PM Ask5:29:55 PM Market Capitalization Dividend Y. P/E Ratio
169.00SEK +1.68% 1.29 mill.
Turnover: 211.23 mill.
170.00Bid Size: - 170.30Ask Size: - 45.55 bill.SEK 0.00% 18.84

Business description

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
 

Management board & Supervisory board

CEO
Guido Oelkers
Management board
Henrik Stenqvist, Amy Pott, Anne Marie de Jonge Schuermans, Armin Reininger, Milan Zdravkovic, Norbert Oppitz, Paula Treutiger, Philip Wood, Sofiane Fahmy, Torbjörn Hallberg
Supervisory board
Håkan Björklund, Annette Clancy, Björn Ohlsson, David Allsop, Elisabeth Svanberg, Hans GCP Schikan, Helena Saxon, Katy Mazibuko, Kristin Strandberg, Lennart Johansson, Linda Larsson, Matthew Gantz, Pia Axelson
 

Company data

Name: Swedish Orphan Biovitrum AB
Address: -,SE-112 76 Stockholm
Phone: +46-8-697-2000
Fax: +46-8-697-2330
E-mail: -
Internet: www.sobi.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 38.52%
IPO date: -

Investor relations

Name: Paula Treutiger
IR phone: +46-73-366-6599
IR Fax: -
IR e-mail: paula.treutiger@sobi.com

Company calendar

CW 16 | 4/15/2020 4th Quarter/Annual Report
CW 18 | 4/29/2020 Interim Report 1st Quarter/3 Months
CW 20 | 5/13/2020 General Shareholder Meeting
CW 29 | 7/16/2020 Interim Report 2nd Quarter/6 Months
CW 43 | 10/22/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
38.52%
Investor AB
 
35.87%
BNY Mellon NA (former Mellon)
 
9.82%
Morgan Stanley Smith Baney LLC
 
8.07%
State Street Bank
 
4.58%
Fjärde AP-fonden
 
3.14%
Others
 
0.00%